Bright Minds Biosciences Inc. (CSE: DRUG | NASDAQ: DRUG), a clinical-stage biotechnology company focused on CNS disorders, announced it will participate in the Foundation for Prader-Willi Research 2026 Research Symposium (October 7–8) and PWS Family Conference (October 9–10) at the Marriott Philadelphia Downtown. The company's attendance highlights its advancing NOVA Phase 2a study of BMB-101 for Prader-Willi Syndrome, a rare genetic disorder affecting approximately one in every 15,000 live births. The announcement also includes a corporate share option rescission involving 44,500 common shares.

Key Points

  • Bright Minds Biosciences Inc. (CSE: DRUG | NASDAQ: DRUG) is a clinical-stage biotechnology company developing selective 5-HT2 agonists for CNS disorders
  • The company will participate in the FPWR 2026 Research Symposium and PWS Family Conference in Philadelphia on October 7–10, 2026
  • BMB-101 is under evaluation in NOVA, a randomised, double-blind, placebo-controlled Phase 2a study measuring hyperphagia over a 16-week treatment period with an optional open-label extension
  • Investors may be watching for updates from NOVA study enrolment progress and data readouts as the clinical programme advances

Bright Minds Targets Full PWS Symptom Burden With BMB-101

Prader-Willi Syndrome is characterised by hyperphagia — a chronic, life-threatening hunger condition — alongside significant neurobehavioural challenges including emotional dysregulation, compulsivity, and cognitive impairment. The release states that currently available therapies address hyperphagia only, with no approved treatments existing for the neurobehavioural symptoms. Bright Minds is developing BMB-101, a highly selective, Gq-biased 5-HT2C agonist, designed to restore signalling through the 5-HT2C receptor pathway, which regulates appetite, satiety, and behaviour, while avoiding cardiac liabilities associated with earlier serotonergic agents.

NOVA Phase 2a Study Design and Primary Endpoint

BMB-101 is being evaluated in NOVA, a randomised, double-blind, placebo-controlled Phase 2a study. The primary endpoint is the change from baseline in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), with additional assessments of PWS-associated behaviours and safety and tolerability across a 16-week treatment period. An optional open-label extension is also included in the study design. The company did not disclose current enrolment figures or an anticipated data readout timeline in this announcement.

Scientific Advisory Board Expansion and FPWR Community Engagement

In November 2025, Bright Minds expanded its Scientific Advisory Board with four global PWS specialists, including Theresa V. Strong, PhD, a founding member of FPWR and its Director of Research Programs; Jennifer L. Miller, MD, of the University of Florida; Elizabeth Roof of Vanderbilt University; and Tania Markovic of Royal Prince Alfred Hospital, Sydney. Participation in the FPWR conference reflects the company's stated commitment to keeping the PWS patient and research community engaged as the clinical programme progresses.

Stock Option Rescission Results in Return of 44,500 Shares to Treasury

Separately, the company announced a mutual rescission and release agreement with an officer of the company, rescinding that officer's prior exercise of stock options relating to 44,500 common shares. The release states the 44,500 shares will be returned to treasury and cancelled, the aggregate exercise price will be refunded to the officer, and the options will be restored on their original terms, including exercise price, vesting schedule, and expiry date. The company confirmed no other options are affected. The immediate share price impact was not clear from available public information.